TY  - JOUR
AU  - Hajek, Roman
AU  - Pour, Ludek
AU  - Ozcan, Muhit
AU  - Martin Sánchez, Jesus
AU  - García Sanz, Ramon
AU  - Anagnostopoulos, Achilles
AU  - Oriol, Albert
AU  - Cascavilla, Nicola
AU  - Terjung, Andreas
AU  - Lee, Yihua
AU  - Briso, Eva M
AU  - Dobkowska, Edyta
AU  - Hauns, Bernhard
AU  - Špička, Ivan
PY  - 2020
DO  - 10.1111/ejh.13377
UR  - http://hdl.handle.net/10668/14899
T2  - European journal of haematology
AB  - We evaluated ibrutinib, a once-daily inhibitor of Bruton's tyrosine kinase, combined with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma who had received 1-3 prior therapies. This was a phase 2,...
LA  - en
KW  - bortezomib
KW  - dexamethasone
KW  - ibrutinib
KW  - multiple myeloma
KW  - Adenine
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Bortezomib
KW  - Dexamethasone
KW  - Drug Resistance, Neoplasm
KW  - Female
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Male
KW  - Middle Aged
KW  - Multiple Myeloma
KW  - Neoplasm Staging
KW  - Piperidines
KW  - Prognosis
KW  - Recurrence
KW  - Retreatment
KW  - Treatment Outcome
TI  - A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
TY  - research article
VL  - 104
ER  -